{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:20:55Z","timestamp":1788668455030,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bneo.2024.100043","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T02:39:22Z","timestamp":1726713562000},"page":"100043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8484-175X","authenticated-orcid":false,"given":"Amrita Y.","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-6526","authenticated-orcid":false,"given":"Meera","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca W.","family":"Silbermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8193-1418","authenticated-orcid":false,"given":"Ziji","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3127-7101","authenticated-orcid":false,"given":"Scott R. P.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith E.","family":"Stockerl-Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.bneo.2024.100043_bib1","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: emerging trends and challenges","volume":"14","author":"Dima","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100043_bib2","article-title":"TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion","volume":"198","author":"Smithson","year":"2017","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100043_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bneo.2024.100043_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100043_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/cells9010077","article-title":"Is there a future for anti-CD38 antibody therapy in systemic autoimmune diseases?","volume":"9","author":"Benfaremo","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bneo.2024.100043_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.bneo.2024.100043_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"S10","key":"10.1016\/j.bneo.2024.100043_bib8","article-title":"The anti-CD38 monoclonal antibody TAK-079 depletes antibody secreting cells from normal and SLE patients [abstract]","volume":"68","author":"Wang","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100043_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/jpet.119.256602","article-title":"A\u00a0reduction in B, T, and natural killer cells expressing CD38 by TAK-079 inhibits the induction and progression of collagen-induced arthritis in cynomolgus monkeys","volume":"370","author":"Korver","year":"2019","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.bneo.2024.100043_bib10","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3324\/haematol.2020.268656","article-title":"Comparison of CD38 antibodies in\u00a0vitro and ex\u00a0vivo mechanisms of action in multiple myeloma","volume":"106","author":"Kinder","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bneo.2024.100043_bib11","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"Fedyk","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100043_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.bneo.2024.100043_bib14","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2024.100043_bib15","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2024.100043_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2052658","article-title":"Anti CD38 monoclonal antibodies for multiple myeloma treatment","volume":"18","author":"Gozzetti","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.bneo.2024.100043_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines Insights: multiple myeloma, version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.bneo.2024.100043_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.bneo.2024.100043_bib22","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A\u00a0phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2024.100043_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2019-02-895193","article-title":"A\u00a0phase 1b study of isatuximab plus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma","volume":"134","author":"Mikhael","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bneo.2024.100043_bib24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.bneo.2024.100043_bib25","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2016-07-726729","article-title":"Phase 1\/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"128","author":"Plesner","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100043_bib26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2024.100043_bib27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/ph16030415","article-title":"Past, present, and a glance into the future of multiple myeloma treatment","volume":"16","author":"Elbezanti","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.bneo.2024.100043_bib28","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3026(19)30249-2","article-title":"MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10214","key":"10.1016\/j.bneo.2024.100043_bib29","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bneo.2024.100043_bib30","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100043_bib33","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2024.100043_bib34","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bneo.2024.100043_bib43","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:49:06Z","timestamp":1756255746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2950328024000438"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100043","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed\/refractory multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100043"}}